Additional supporting information may be found in the online version of this article at the publisher's web-site.


Figure S1. The chemical structure of ONO-5334. ONO-5334 (N-((1S)-3-{(2Z)-2-[(4R)-3,4-dimethyl-1,3-thiazolidin-2-ylidene]hydrazino}-2,3-dioxo-1-(tetrahydro-2H-pyran-4-yl)propyl) cycloheptanecarboxamide) (Ono Pharmaceutical Co., Ltd., Osaka, Japan).

Figure S2. Goodness of fit plots for (a) plasma concentration of ONO-5334, (b) %CFB LS BMD, and (c) %CFB Hip BMD. CWRES, conditional weighted residuals. The symbols of square represent observed data. Solid curve and line represent LOESS (locally weighted scatterplot smoothing) fit and unity, respectively. %CFB, percent change from baseline; LS, lumbar spine; Hip, total hip; BMD, bone mineral density.

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.